Sellas shares rise after Phase 3 trial shows survival benefit
In short
Sellas shares rose after its Phase 3 trial of GPS showed a strong survival benefit for people with acute myeloid leukemia. The company said there were no new safety concerns, and it plans to talk with the US FDA about an accelerated filing path.
The stock had already jumped 156% in one day and then gained another 5%. That keeps investors focused on the drug and the planned 2027 filing.
What the reporting says
Sellas shares rose after its Phase 3 trial of GPS showed a significant survival benefit for patients with acute myeloid leukemia, with no new safety concerns reported. The company said it plans to discuss an accelerated filing strategy with the US FDA and aims to submit an application in 2027. The stock had already surged 156% in a day before adding another 5%.
Why it matters
Sellas is drawing investor attention after reporting Phase 3 results for GPS in acute myeloid leukemia. The trial showed a significant survival benefit and no new safety concerns, according to the summary. The company said it will discuss an accelerated filing strategy with the FDA and targets an application in 2027, which could shape expectations for the biotech stock.